Search results
• Updated WHO guidelines review the recommendation to treat all HCV-infected people over 12 years of age (except pregnant women) • The use of DAAs leads to high cure associated with a decrease in HCC mortality and incidence (according to the studies using IFN) • SVR is associated with the improved course of comorbidities such as diabetes,
- Recommendations and guidance on hepatitis C virus self-testing
The new WHO guidelines provide a recommendation and new...
- Recommendations and guidance on hepatitis C virus self-testing
17 mar 2023 · CDC is augmenting previous guidance with two new recommendations: 1) hepatitis C screening at least once in a lifetime for all adults aged ≥18 years, except in settings where the prevalence of HCV infection is <0.1% and 2) hepatitis C screening for all pregnant women during each pregnancy, except in settings where the prevalence of HCV ...
15 lip 2021 · The new WHO guidelines provide a recommendation and new guidance on HCV self-testing (HCVST). HCVST is a private and convenient testing option that can be particularly useful for reaching people with HCV who do not otherwise test using existing services and who may prefer self-care options.
Recognizing the importance of timely guidance regarding the rapidly evolving field of hepatitis C management, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) developed a ...
19 gru 2023 · CDC recommends universal hepatitis C screening for all adults 18 and older and all pregnant people during each pregnancy. CDC recommends testing people in certain high-risk groups more frequently. Testing, diagnosis, and timely treatment can prevent hepatitis C complications and interrupt transmission.
25 maj 2023 · For initial HCV testing, the Guidance Panel recommends HCV antibody screening with reflex HCV RNA testing to establish the presence of active infection (as opposed to spontaneous or treatment-induced viral clearance).
Hepatitis C screening at least once in a lifetime for all adults aged ≥18 years, except in settings where the prevalence of hepatitis C virus (HCV) infection (HCV RNA-positivity) is <0.1%*.
